Announcements Trials
Browse Landscape

Phase

Phase 3 16Phase 2 7Phase 4 5Phase NA 2Phase 2/3 1Phase 1/2 1

Status

Recruiting 9Completed 7Terminated 6Unknown 4Active not recruiting 4Withdrawn 1

Sponsor Class

NETWORK 3OTHER 2INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 3Breast 3Head & Neck 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 2Salivary Gland Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Invasive Nos 1Adenocarcinoma 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Completed × Triptorelin Pamoate × Clear all
NCT05896566 2026-02-24

PREcoopERA

ETOP IBCSG Partners Foundation

Phase 2 Completed
231 enrolled
Breast

Breast Neoplasms

NCT02278185 2025-05-11

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

University of Colorado, Denver

Phase 2 Completed
19 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
149 enrolled
Head & Neck

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT04659551 2020-12-09

GIADA

Istituto Oncologico Veneto IRCCS

Phase 2 Completed
43 enrolled
Breast

Breast Neoplasms

NCT01790126 2020-03-11

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Aragon Pharmaceuticals, Inc.

Phase 2 Completed
90 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed
51 enrolled 10 charts
Breast

Breast Cancer Invasive Nos

NCT01257425 2019-02-08

PAMIS

Ipsen

Phase 2 Completed
109 enrolled 22 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡